Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma

NCT02094872 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT02094872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02094872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2014
Completion date
December 31, 2018
Enrollment
49 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent melanoma, stage iiia melanoma, stage iiib melanoma, stage iiic melanoma, stage iv melanoma